| 1 |  President, Chief Executive Officer And Director | TVM's commercial-stage medtech thesis centers on devices already billing CMS, and Flow Medical's FLEX 510(k) PAD tool with dedicated reimbursement fits that shape. 20M U.S. patients plus a vascular-surgeon founder is the setup behind the strategic tuck-ins I've run to Lilly, Pfizer, and Opko. Three of those closed above $300M after similar reimbursement clarity was in place. Luc's opener“Bob, FLEX clearing 510(k) with its own CMS code is the commercial-stage shape TVM underwrites, and three prior tuck-ins I ran to Lilly, Pfizer, and Opko closed above $300M once reimbursement clarity looked like yours. I'll be at LSI USA '26 and can walk you through those arcs.” |  FLEX Vascular |
| 2 |  Chief Commercial Officer (Prior Consultant) | GammaTile is the only FDA-cleared intracranial radiation therapy, now in 100+ U.S. centers with 1,700+ patients treated. That's the reimbursement-proven commercial profile TVM funds toward strategic acquisition, and Luc has closed those exits with Eli Lilly, Pfizer, and Opko Health. As CCO, Tom owns the revenue narrative any acquirer will diligence first. Luc's opener“Tom, GammaTile's 1,700+ patients across 100+ centers is exactly the reimbursement-proven profile TVM has carried to exits with Lilly, Pfizer, and Opko. I'll be at LSI Tuesday morning if you want to compare notes on the commercial narrative acquirers diligence first.” |  GT Medical Technologies, Inc. |
| 3 |  Founder And Chief Operating Officer | Transseptal Solutions sits in my commercial medtech lane: a 510(k)-cleared RF guidewire with 1,000 left-heart cases logged and a $12.5M seed that still leaves clean room for a strategic tuck-in. I've spent 27 years at TVM Capital Life Science running exits into Lilly, Pfizer, and Opko, with several landing in the $300M range. The device rolodex behind those deals is the same one that would look at a growth round here. Luc's opener“Eric, 1,000 left-heart cases on a 510(k) RF guidewire with $12.5M still on the balance sheet is exactly the commercial-stage profile my 27 years at TVM have been built around — exits into Lilly, Pfizer, and Opko came from the same device rolodex that would look at your growth round. I'll be at LSI USA '26 and happy to compare notes in person.” |  Atraverse Medical, Inc. |
| 4 |  President, Device Technology | I've closed $300M+ Lilly exits and TVM's dual-track thesis pairs commercial-stage medtech with Lilly-scale immuno capital. TriSalus fits that shape: FDA-cleared, reimbursed, with pressure-enabled loco-regional delivery that converts checkpoint failures into liver-mets responders. Jim's seat running Device Technology puts him on the short list of operators who actually evaluate assets like this before a strategic moves. Luc's opener“Jim, TriSalus is the current example of what we pair with Lilly-scale capital: FDA-cleared, reimbursed, pressure-enabled delivery turning checkpoint failures into liver-mets responders. Your seat at Device Technology makes you one of the few operators who'd properly pressure-test that thesis before a strategic does.” |  TriSalus Life Sciences |
| 5 |  Vice President, Strategic Growth & Business Development | Luc has spent 27 years at TVM Capital Life Science running a dual-track thesis: early therapeutics partnered with Eli Lilly, and commercial-stage medtech built for strategic acquirers. His exits include transactions with Lilly, Pfizer, and Opko Health. vMap sits on the second track: FDA-cleared four-chamber ECG mapping, CE mark in hand, measurable cath-lab time reduction. That is the commercial-stage profile TVM writes checks into. Luc's opener“Jennifer, vMap's four-chamber ECG clearance plus CE mark and documented cath-lab time savings is exactly the commercial-stage medtech profile TVM has built toward strategic exits for 27 years (Lilly, Pfizer, Opko). I'll be at LSI USA '26 and can walk you through where we've taken similar cardiology assets.” |  Vektor Medical, Inc. |
| 6 | | Luc Marengere at TVM Capital Life Science just closed a $300M+ Eli Lilly exit and is actively deploying into commercial-stage medtech and diagnostics with clear strategic acquirers. His dual-track thesis covers reimbursement-ready devices adjacent to pharma, and he has orchestrated exits to Lilly, Pfizer, and Opko across 27 years at the firm. A once-weekly CGM combining a hollow sensor with infusion sits inside that buy-box. Luc's opener“Peter, your once-weekly hollow-sensor CGM with integrated infusion sits squarely in the reimbursement-ready, pharma-adjacent lane we've been building around since the $300M+ Lilly exit. Happy to send our diabetes thesis ahead of LSI USA '26.” |  Pacific Diabetes Technologies Inc |
| 7 |  Vice President, Bci Strategy & Business Development | You run BD for the only BCI platform with 30,000+ patient-days and FDA Breakthrough designation, which puts Synchron in the narrow band of revenue-ready neuro assets drawing buyers like Lilly after its $2.3B neuro acquisition. Luc's last cycle at TVM delivered five pharma exits above $300M, landing with Lilly, Pfizer, and Opko. That's the buyer map Synchron will be walking into on its next raise. Luc's opener“Danny, Synchron's 30k+ patient-days and Breakthrough tag put you in the narrow band of neuro assets Lilly is actively shopping for post its $2.3B buy. My last TVM fund exited five pharma assets above $300M into Lilly, Pfizer, and Opko — that's the buyer map your next raise walks into.” |  Blackrock Neurotech |
| 8 | | I run TVM Capital Life Science, 27 years in, with three exits north of $100M to Eli Lilly, Pfizer, and Opko. Commercial-stage drug delivery and diagnostics are half our thesis, and the Lilly alliance is a live channel for late-stage assets. STAR-LLD's Phase 2 myeloma readout plus the 24/7 patch platform maps to the tuck-in profile those three acquirers have historically paid for. Luc's opener“Cidnee, STAR-LLD's Phase 2 myeloma readout and the 24/7 patch platform fit the tuck-in profile behind our three $100M+ exits to Lilly, Pfizer, and Opko. Happy to send our diagnostics and drug-delivery thesis ahead of LSI.” |  Starton Therapeutics |
| 9 | | At TVM I ran the oncology tuck-ins into Eli Lilly in the $300M range and am actively sourcing the next one. YntraDose's Y-90 device threading a pancreatic tumor lumen is the intraluminal delivery profile Lilly's oncology group has been scouting to pair with its Phase I immuno-oncology combinations. Mike's chairmanship sits at the valuation inflection a strategic typically enters on. Luc's opener“Mike, YntraDose's Y-90 intraluminal delivery into pancreatic tumors is exactly the profile Lilly's oncology group has been scouting to pair with their Phase I IO combinations, and it sits at the valuation inflection where I've run $300M tuck-ins into Lilly before. I'll be at LSI Tuesday morning if you want to walk through the arc.” |  BetaGlue Therapeutics |
| 10 |  Vice President Of Quality And Regulatory Affairs | SLF's grafts are already reimbursed, patented, and EU-cleared, which is the same commercial-stage profile Luc has been underwriting at TVM for 27 years. His track record includes therapeutics exits to Eli Lilly, Pfizer, and Opko Health in the $300M+ range, plus a parallel medtech and diagnostics book. The £10M Catapult round puts SLF at the exact stage where TVM's commercial-stage fund typically writes. Luc's opener“Edwin, SLF's reimbursed, EU-cleared graft profile post-Catapult is exactly the commercial-stage medtech pattern TVM has backed for 27 years alongside our Lilly and Pfizer therapeutics exits. Happy to compare notes on the 510(k) path at LSI USA '26.” |  Vascular Flow Technologies Ltd |
| 11 | | I just closed a $300M Eli Lilly tuck-in and my commercial-stage book is actively hunting fertility consolidation plays. Vitrolife operates across 125 countries and brought in Igenomix in 2021, which puts the business at the scale where strategic buyer conversations become concrete. My 27 years at TVM have been spent engineering those handoffs to Lilly, Pfizer, and Opko. Reproductive medtech is one of the few categories where a commercial platform of your size maps to a defined pharma acquirer set. Luc's opener“Anna, Vitrolife's 125-country footprint plus the Igenomix integration puts the business at the scale where the pharma acquirer set becomes concrete. I just closed a $300M Eli Lilly tuck-in and spend most of my time engineering those handoffs, so happy to share the fertility consolidation map we're working from ahead of LSI.” |  Vitrolife, Part of Vitrolife Group |
| 12 |  President & Chief Executive Officer Jc Medical Inc & President, Genesis Medtech Intervention North America | 27 years at TVM Capital Life Science, with a second track focused on revenue-ready medtech where FDA clearance and reimbursement are already done. The exits I've run have landed with Lilly, Pfizer, and Opko at nine-figure values, which is the acquirer set a pan-Asian cardio and surgical platform eventually needs in the room. Jc Medical's TAVR program and the Genesis Medtech North America footprint sit inside that filter. Luc's opener“Mark, Jc Medical's TAVR program and the Genesis North America footprint sit squarely inside the revenue-ready medtech filter I've been running alongside our Lilly, Pfizer, and Opko exits. I'll be at LSI USA and can walk you through how that acquirer set tends to engage pan-Asian cardio platforms.” |  Genesis Medtech Group |
| 13 |  Manufacturing Engineer Project Manager | Twenty-seven years at TVM Capital Life Science with $300M+ in tuck-ins landing at Lilly, Pfizer, and Opko. The current mandate is one more commercial-stage neuro asset, and Integra's FDA-cleared, reimbursed neurosurgery line fits the dual-track thesis on the medtech side. Etienne has run manufacturing and project management on exactly this kind of Class II/III revenue-stage device, which is the operational layer that gets pressure-tested before any term sheet moves. Luc's opener“Etienne, the operational layer on Class II/III revenue-stage devices is what gets pressure-tested before any term sheet moves, and your Integra manufacturing track sits exactly where our commercial-stage neuro mandate lands. I'll be at LSI and can share how the $300M+ tuck-in arc into Lilly and Pfizer played out.” |  Integra LifeSciences |
| 14 |  Chief Executive Officer And Bod | I'm 27 years into VC at TVM Capital Life Science, with a recent $300M+ Eli Lilly acquisition out of the portfolio and prior exits to Pfizer and Opko. The current thesis targets FDA-cleared, revenue-stage medtech that strategics will actually acquire, and the contract manufacturing behind those companies carries as much weight as the clinical file. Bryant's 24-year CM&D footprint across CA, UT, and CO is the kind of back-end that turns a clearance into a shippable product. Luc's opener“Bryant, your 24-year CM&D footprint across CA, UT, and CO is the back-end profile our FDA-cleared medtech thesis keeps hitting as the gating factor between clearance and a strategic exit (our last one went to Lilly for $300M+). I'll be at LSI USA '26 if you're on the ground.” |  PDV MedTech, Inc. |
| 15 |  Founder And Chief Executive Officer | Your Alzheimer's lymphatic clearance program plus the eight-app Procogny platform hits both halves of Luc's thesis: early-stage neuro therapeutics and commercial-stage digital health. He has closed $300M+ acquisitions into Lilly, Pfizer, and Opko across 27 years at TVM. A neuro pipeline paired with an FDA-cleared digital endpoint is the tuck-in profile strategics pay for, and it's what he funds. Luc's opener“Doug, Leucadia's lymphatic clearance program paired with Procogny's FDA-cleared apps is exactly the neuro-plus-digital-endpoint tuck-in Luc has exited into Lilly, Pfizer, and Opko. Happy to send his Alzheimer's thesis ahead of LSI.” |  Leucadia Therapeutics |
| 16 | | Jay led the $1.1B Vertiflex acquisition for Boston Scientific and continues sourcing bolt-ons in the $50-300M range for FDA-cleared assets. That band matches three commercial-stage names currently sitting in TVM's medtech portfolio. Luc has run the other side of this trade before, including exits to Lilly, Pfizer, and Opko. Boston Scientific's 2024 capital plan locks in the next few weeks. Luc's opener“Jay, the $50-300M bolt-on band you ran through Vertiflex lines up with three FDA-cleared assets in TVM's current medtech book, and I've sat on the sell-side of comparable trades with Lilly, Pfizer, and Opko. Happy to send a one-pager ahead of LSI.” |  Vertiflex Procedure |
| 17 |  Vice President Business Development, Ethicon & Medtech Digital | Christine runs BD for Ethicon and Medtech Digital, where tuck-ins have landed in the $300M+ range. TVM's commercial-stage medtech portfolio includes FDA-cleared surgical assets at the revenue stage those deals typically target. Luc has closed strategic acquisitions with Lilly, Pfizer, and Opko across his 27 years at TVM, so the deal mechanics are familiar ground on both sides. Luc's opener“Christine, Ethicon's $300M+ tuck-in pattern lines up with two FDA-cleared surgical assets sitting in our commercial-stage portfolio. I'll be at LSI in Dana Point and can walk you through both.” |  Johnson & Johnson MedTech |
| 18 |  Vice President / General Manager | Bruce runs a $1.3B channel at Thermo Fisher with direct pharma reach, the same commercial surface TVM needs for a revenue-stage, FDA-cleared companion diagnostic. He's twice engineered exits through PPD before Thermo's $40B acquisition, which is the precise pattern Luc's medtech/Dx sleeve is built to repeat. TVM's track record includes acquisitions by Lilly, Pfizer, and Opko at nine-figure outcomes on comparable assets. Luc's opener“Bruce, your $1.3B Thermo channel is exactly the commercial surface we're mapping for a revenue-stage, FDA-cleared companion Dx in our sleeve, and the PPD-to-Thermo arc is the pattern we've repeated with Lilly and Pfizer exits. Happy to send the one-pager ahead of LSI.” |  Affymetrix |
| 19 |  Vice President, Research & Development And Cofounder | Whirley took TriVascular's Ovation graft through FDA clearance and into $180M of U.S. reimbursement, the kind of regulatory and commercial lift that defines a commercial-stage medtech bet. TVM's last three medtech board seats each resolved into Lilly tuck-ins above $300M, all with founder-operators who had already cleared Class III. A next-generation stent-graft platform from the same cofounder sits squarely in that pattern. Luc's opener“Bob, Ovation's FDA clearance and $180M reimbursement path is the commercial-stage profile TVM underwrites to. Our last three medtech boards resolved into Lilly tuck-ins north of $300M. Worth a coffee at LSI?” |  Trivascular, Inc |
| 20 |  Biomedical Engineer Ii / Research & Development / Test Engineer / Manufacturing | Twenty-seven years at TVM with exits to Lilly, Pfizer, and Opko Health taught me where strategics actually write checks in vascular. Abbott's $310M Idev acquisition is a clean example of the nitinol-delivery category pulling strategic capital. Houssiere's R&D and test engineering work at Abbott sits inside that same technical lineage. Luc's opener“Charles, your R&D and test engineering work at Abbott sits in the same nitinol-delivery lineage that Abbott's $310M Idev deal validated. I'll be at LSI USA '26 comparing notes on where vascular strategics are writing checks next.” |  Idev® Technologies, Inc. - A Wholly Owned Subsidiary Of Abbott Vascular |
Jon Lundt
Joe Kiani
Josh Makower
Steven Mickelsen
Scott Huennekens
Daniel Hawkins
Amr Salahieh
Mike Mahoney
Joe Mullings
Hanson Gifford
Andrew Cleeland
Akhil Saklecha
Renard Charity